Kornimate/medical-research-clean huggingface dataset:
adding phosphorus to osteoporosis drug treatment

Conditions: Osteoporosis; Osteopenia

Summary: osteoporosis causes bones to weaken and break more easily. calcium and phosphorus are two minerals that are essential for normal bone formation. unfortunately, calcium salts commonly prescribed in anti-osteoporosis treatment bind phosphorus from food and restrict phosphorus available for bone building. teriparatide is a drug that reduces the risk of fractures by increasing bone thickness and strength. vitamin d is also necessary for strong bones and teeth. the purpose of this study is to evaluate the bone-building effectiveness of two calcium supplements, one with a source of phosphorus and one without, in combination with teriparatide and vitamin d in women with osteoporosis.

osteoporosis is the most common type of bone disease. calcium supplements normally used in anti-osteoporosis treatment are calcium salts of carbonate or citrate; however, these salts bind phosphorus from food in the intestine and restrict phosphorus available for bone building. this study will evaluate the efficacy of adding calcium phosphate to a regimen of teriparatide and vitamin d in increasing bone mineral density in women with osteoporosis. it is hypothesized that the group taking the phosphate-containing calcium supplement will have greater gains in bone mineral density (bmd) during the course of the study than the group not receiving phosphate. all participants will receive teriparatide and vitamin d during the course of the 12-month study. participants will be randomly assigned to one of two groups. one group will receive calcium phosphate and the other will receive calcium carbonate. bmd will be measured at spine and hip at baseline and at 3, 6, and 12 months of treatment.

Eligibility criteria:
inclusion criteria: * bone mineral density (bmd) t-score less than -1.0 * one or more vertebral fractures * serum creatinine less than 1.3 mg/dl * serum phosphorus less than 3.6 mg/dl * daily phosphorus intake below nhanes-iii median * body mass index (bmi) less than 30 kg/m2 exclusion criteria: * paget's disease or history of osteosarcoma * systemic corticosteroid therapy * hyperparathyroidism * recent history of kidney stone * anticonvulsant therapy known to alter vitamin d metabolism * radiation therapy to bone

Keywords: bone mineral density calcium
evaluation of st2 and il-33 in patients presenting to the emergency department with trouble breathing

Conditions: Chronic Obstructive Pulmonary Disease; Asthma; Pulmonary Embolism; Pneumonia; Congestive Heart Failure

Summary: trouble breathing (dyspnea) is a nonspecific symptom associated with many diseases such as chronic obstructive pulmonary disease (lung disorder in which the flow of air to the lungs is blocked), asthma, pneumonia, pulmonary hypertension (high blood pressure in the lungs), congestive heart failure (fluid build-up in the lungs because the heart is not pumping normally) and pulmonary embolism (blood clot in the lungs). the purpose of this study is to test two blood markers called st2 and il-33. blood markers are proteins or other compounds in your blood that physicians use to diagnose different diseases and to determine what the course of an illness will be. in preliminary research studies, st2 and il-33 have been elevated in patients with a wide variety of diseases where the lungs are the primary organs involved. this research study will further investigate the ability of st2 and il-33 to predict the severity of disease and the possible use of st2 and il-33 in the diagnosis of various lung diseases.


Eligibility criteria:
inclusion criteria: * presenting to the emergency department with signs and symptoms of dyspnea (short of breath, tachypnea, hyperventilation, etc) within the last 24 hours * normal cardiac output as measured by noninvasive bioimpedance * greater than or equal to 18 years of age * patient or legal representative willing and able to provide informed consent and comply with study procedures exclusion criteria: * ecg changes diagnostic of acute myocardial ischemia/infarction * ischemic chest pain within the prior 24 hours by history * obvious chest trauma exclusion criteria for blood draw: * a history of congestive heart failure and a bnp \> 500pg/ml (or ntprobnp \> 900pg/ml) if obtained by the treating physician * treating physician suspects patient has new onset congestive heart failure

Keywords: dyspnea shortness of breath trouble breathing st2 il-33
a study of the antiplatelet effects comparing ticagrelor (ticag. - azd6140) with clopidogrel (clop.) responder and non-responders

Conditions: Stable Coronary Artery Disease

Summary: the purpose of this study is to see how ticagrelor, a new oral reversible anti-platelet medication, affects platelets. anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. this study investigated the effect of ticagrelor on inhibition of platelet aggregation compared with clopidogrel in patients previously identified as non-responsive to clopidogrel.


Eligibility criteria:
inclusion criteria: * patients with documented stable coronary artery disease (cad) (stable angina, previous mi history, previous history of revascularization) * females of child bearing potential must have a negative pregnancy test prior to receiving study drug and be willing to use a hormonal contraceptive in addition to double barrier contraception exclusion criteria: * history of acute coronary syndromes within 12 months of screening or need for revascularization (angioplasty or coronary artery bypass graft (cabg)) * any acute or chronic unstable condition in the past 30 days * have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high blood pressure, low platelet count, recent major trauma * history of intolerance or allergy to aspirin or clopidogrel

Keywords: coronary artery disease (cad) heart attack stable angina
what amount of stress is enough for a successful conception?

Conditions: In Vitro Fertilization; Stress; Midazolam Adverse Reaction; Stress, Emotional

Summary: the aim of the study is to determine whether premedication with midazolam before oocyte aspiration in ivf procedures affects the amount of (oxidative) stress in women undergoing ivf and whether stress is also transmitted to the follicular fluid of aspirated follicles. the primary endpoint is the impact of stress during aspiration on the success of medically assisted fertilization (ivf / icsi in the stimulated cycle).

the procedure of in vitro fertilisation (ivf) is used to treat the infertility problems. the procedure includes ovary aspiration, to isolate oocytes. during the aspiration the patient is sedated with short-term intravenous aesthetic. premedication is often used in anaesthesiology, and includes drugs application 30 minutes prior to procedure to sedate and treat the anxieties of the patient. one of the most often used drugs in premedication is midazolam. as the procedure is quite stressful for the patients, our aim is to investigate the influence of midazolam premedication on the stress release during the oocyte aspiration procedure, as well as its influence on the whole ivf procedure. therefore, patients will be divided into two groups, control and midazolam. blood samples will be taken before and during the procedure. stress, antioxidant parameters (with glutathione and catalase) and oxidative status will be monitored in serum and follicular fluid. the results will be correlated with subjective stress levels in the two groups in an effort to establish ties with ivf results.

Eligibility criteria:
inclusion criteria: * informed consent, healthy women undergoing ivf procedures for the first time exclusion criteria: * refusal to enroll, chronic endocrine and psychiatric illnesses that might affect baseline stress levels

Keywords: ivf stress midazolam premedication
follow-up of endovascular aneurysm treatment - the feat trial

Conditions: Aortic Aneurysm, Abdominal

Summary: after endovascular abdominal aortic aneurysm repair, life-long follow-up is needed to monitor the effectiveness of exclusion of the aneurysm sac from blood flow. for this reason, aneurysm diameter and the presence of endoleaks is evaluated with ct angiography yearly after endovascular aneurysm repair (evar). the aim of this study is to investigate the value of mra examinations for the follow-up of these patients. the advantages of mra with respect to cta are no use of ionizing radiation, use of less nephrotoxic contrast agents.

the feat trial (follow-up of endovascular aneurysm treatment) is designed as a prospective, single-center, follow-up study. 100 patients will be enrolled in this study. these patients will undergo additional mra-examinations the day before evar, the day after evar, 6 months and 1 year after evar. these patients also participate in the conventional cta follow-up scheme which comprises a pre- and post-operative cta and a cta yearly thereafter. coagulation parameters in the blood will be measured before and 1 year after evar.

Eligibility criteria:
inclusion criteria: * patient is planned for endovascular abdominal aortic aneurysm repair exclusion criteria: * contraindication for mri examination * claustrophobia * pacemaker * other non-mri compatible implants

Keywords: blood vessel prosthesis implantation endovascular aneurysm repair magnetic resonance angiography computed tomography angiography endoleak
this was a dose-finding study to evaluate efficacy and safety of lou064 in patients with csu inadequately controlled by h1-antihistamines

Conditions: Chronic Spontaneous Urticaria

Summary: this was a multicenter, randomized, double-blind and placebo-controlled phase 2b dose-finding study to assess the efficacy and safety of lou064 in adults chronic spontaneous urticaria (csu) patients inadequately controlled by h1-antihistamines

this was a global phase 2b multicenter, randomized, double-blind, parallel-group, placebo-controlled study investigating the efficacy, safety and tolerability of six dosing groups of oral lou064 in subjects with inadequately controlled csu despite treatment with (second generation) h1-antihistamine. the study comprised of the 7 treatment arms: lou064 10 mg q.d., lou064 35 mg q.d., lou064 100 mg q.d., lou064 10 mg b.i.d, lou064 25 mg b.i.d., lou064 100 mg b.i.d. and placebo.

Eligibility criteria:
inclusion criteria: * male and female subjects aged ≥18 years of age * csu diagnosis for ≥ 6 months prior to screening * presence of itch and hives for ≥6 consecutive weeks prior to screening in spite of use of non-sedating h1-antihistamines according to local treatment guidelines during this time period * uas7 score (range 0-42) ≥16 and hss7 score (range 0-21) ≥ 8 during 7 days prior to randomization (day 1) * willing and able to complete an urticaria participant daily ediary (updd) for the duration of the study exclusion criteria: * hypersensitivity to any of the study treatments * clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) * other diseases with symptoms of urticaria or angioedema * other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results, * known or suspected history of an ongoing, chronic or recurrent infectious disease including but not limited to opportunistic infections (eg tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis), hiv, hepatitis b/c. * pregnant or nursing (lactating) women * women of child-bearing potential not using highly effective methods of contraception

Keywords: btk inhibitor urticaria activity score angioedema activity score csu
hypotensive anesthesia with sleeve gastrectomy

Conditions: Obesity, Morbid

Summary: to do sleeve gastrectomy under hypotensive anesthesia till compete stapling then hypertensive at the end

to do sleeve gastrectomy under hypotensive anesthesia till compete stapling then hypertensive at the end of the operation to check bleeding

Eligibility criteria:
inclusion criteria: * obese patients with bmi more than 40 or more than 35 with comorbidity * patients fit for laparoscopic surgery * give approval to share in the study exclusion criteria: * patients refused to share in the study * patients unfit for surgery * patients aged less than 18 and older than 50 * patients with bmi less than 35 * patient with previous upper abdominal surgery either for obesity or other diseases * patients with gerd
study of aro-hif2 in patients with advanced clear cell renal cell carcinoma

Conditions: Clear Cell Renal Cell Carcinoma

Summary: the purpose of this study is to evaluate the safety and efficacy of aro-hif2 injection (also referred to as aro-hif2) and to determine the recommended phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccrcc).


Eligibility criteria:
inclusion criteria: * women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception * willing to provide written informed consent and to comply with study requirements * histologically confirmed locally advanced or metastatic clear cell renal cell carcinoma that has progressed during or after at least two prior therapeutic regimens which must include vascular endothelial growth factor (vegf)-targeted therapy and checkpoint inhibitor therapy or that has otherwise failed such therapies, is measurable disease per recist 1.1 criteria, is biopsy accessible * eastern cooperative oncology group (ecog) performance status 0 or 1 * estimated life expectancy of longer than 3 months * adequate organ function at screening exclusion criteria: * history of untreated brain metastasis or leptomeningeal disease or spinal cord compression * failure to recover from reversible effects of prior anti-cancer therapy * has received systemic therapy or radiation therapy within 2 weeks prior to first dose * history of solid organ or stem cell transplantation * current use of anti-vegf or mammalian target of rapamycin (mtor) agents, or chronic immunosuppressive therapy * any prior use of hypoxia inducible factor 2 (hif2) inhibitors within 6 months prior to first dose * current use of immune checkpoint inhibitors * use of an investigational agent or device within 2 weeks prior to dosing, or current participation in an investigational study * known hiv, hepatitis b or hepatitis c * history of other clinically meaningful disease * major surgery within 4 weeks of screening * active malignancy requiring therapy other than ccrcc within 3 years of study entry note: other eligibility criteria may apply per protocol.
internal mammary sentinel lymph node biopsy in early breast cancer patients with clinically axillary node -negative

Conditions: Breast Cancer

Summary: in addition to the axillary lymph node, the internal mammary lymph node (imln) chain is also the first-echelon nodal drainage site for metastasis and provides important prognostic information in breast cancer patients. the internal mammary sentinel lymph node biopsy (im-slnb) provides a less invasive method of assessing the imln than surgical dissection. but the low visualization rate of imsln has been a restriction of im-slnb. this clinical trial is carried out to improve the visualization rate of imsln with modified techniques: (1) the radiotracer is injected intraparenchymally into 2\~4 quadrants of breast. (2) the radiotracer is injected in a high volume. (3) the radiotracer should be injected under ultrasonographic guidance.

objectives: * compare the visualization rate of internal mammary sentinel lymph node in breast cancer patients with different injection technologies. * evaluate the metastasis rate of internal mammary sentinel lymph nodes in patients with clinically axillary node -negative in these patients. * evaluate the risk factors for internal mammary sentinel lymph node metastasis * evaluate the success rate and the safety of internal mammary sentinel lymph node biopsy. * draw the learning curve of internal mammary sentinel lymph node biopsy. outline: 3\~18 hours before surgery, 99mtc-labeled sulfur colloid was injected under ultrasonographic guidance in different patterns and injection methods were classified according to the number of injection quadrants. subsequently, lymphoscintigraphy was performed 0.5\~1.0 hour before surgery. during surgery, the sentinel lymph nodes (axillary or internal mammary) were identified by combining the use of intraoperative gamma detector and blue dye. the sentinel lymph nodes (axillary or internal mammary) were analyzed by hematoxylin-eosin staining and immunohistochemistry for future therapy planning.

Eligibility criteria:
inclusion criteria: * primary breast cancer * clinically axilla-negative exclusion criteria: * enlarged internal mammary nodes by imaging

Keywords: breast cancer sentinel lymph node biopsy internal mammary lymphoscintigraphy
patient assessment of topical anesthetic effectiveness for intravitreal injections

Conditions: Pain

Summary: there are currently several different commercially available topical eye drops and gels used to reduce eye discomfort (topical anesthetics) during and after eye injections. dr. pollack is performing a research study to evaluate three commercially available topical anesthetics (eye numbing treatments) to determine if individuals have a preference for one over the other. the three topical anesthetics being studied are 1) 0.5% proparacaine hydrochloride (generic, akorn, inc), 2) 0.5% proparacaine hydrochloride (generic, akorn, inc) plus 4% lidocaine hydrochloride topical solution (generic, roxane laboratories), and 3) 3.5% lidocaine hydrochloride ophthalmic gel (akten, akorn, inc). these eye anesthetics are not experimental medications. they are all commercially available topical anesthetics currently used in our offices and their use is widespread among retina specialists throughout the united states. dr. pollack will randomly select one topical anesthetic to use and he will ask you to grade your level of pain associated with the injection procedure. answering these questions should take less than one minute of your time and your identity will not be revealed with the results of this study. the results of this study will be used to inform doctors which eye anesthetics patients find most effective for pain control during eye injections.

in this prospective study, 120 sequential patients undergoing 30 and 33 gauge intravitreal injections were randomly assigned to receive either: proparacaine hcl 0.5% (group 1), proparacaine hcl 0.5% + 4% lidocaine liquid drops (group 2); or 3.5% lidocaine gel (group 3) as topical anesthetic prior to injection. all procedures utilized a lid speculum and 5% povidone iodine. approximately 10 seconds after injection, patients graded pain associated with the lid speculum, the needle, and with burning sensation on a pain scale of 0 to 10, with 0 representing no pain and 10 representing the patient's worst imaginable pain. they also graded their overall injection procedure experience as excellent, very good, fair, poor, or awful.

Eligibility criteria:
inclusion criteria: * patients requiring intravitreal injection for treatment of eye disease exclusion criteria: * eye infection * retinal detachment * age less than 18 years * pregnant * unable or unwilling to provide informed consent

Keywords: effectiveness of topical pain medicine for control of pain associated with intravitreal injections eye discomfort
injectable bulking agent needle guide

Conditions: Urinary Incontinence; Intrinsic Sphincter Deficiency

Summary: the purpose of this study is to evaluate the use of the needle guide as an assist in properly guiding an injection needle into the appropriate tissue plane during an injectable bulking agent procedure in women using a fda approved injectable bulking agent. the injectable bulking agent will be durasphere exp.


Eligibility criteria:
individuals satisfying the "indications" and "contraindications" criteria in the durasphere exp directions for use may participate.

Keywords: urinary incontinence isd
intraoral grafting of ex vivo produced oral mucosal composites

Conditions: Mouth Diseases

Summary: the purpose of this study is to see if we can develop a good graft for oral mucosal tissue that is like the top of the mouth in a "test tube" that could be used successfully in humans. we have already done this successfully mice. the next step is to take a small piece of tissue from a human volunteer and see if we can grow a larger piece of tissue from it outside the human body and graft it back into the same person successfully. we expect that this technique will work. it has already been tried in patients with burns of the skin who have had similar procedures where the skin is grafted back to them. the significance of this research is that oral tissue taken from the top of the mouth or palate is in limited supply and leaves the patient with a painful and uncomfortable post surgery experience. if we are successful with our technique the patient will experience less pain and discomfort from the site that we are using to grow our tissue outside the body than if we had taken it from the top of the mouth or palate. in addition, by waiting longer periods to grow the patient's cells we can make larger pieces of oral tissue than we could have gotten directly from the patient's mouth. patients who will participate in this study will need to require a soft tissue graft from the mouth to an area that needs additional attached or keratinized mucosa. this will most likely be either in preparation for patients who have or will have dental implants placed. another subset of patients are those who need scar tissue released or the vestibule of their mouth (area that turns from the gums to the lip) released.


Eligibility criteria:
inclusion criteria: * lack sufficient attached keratinized tissue at recipient surgical site in question

Keywords: mouth mucosa transplants
assessing ocular surface changes after changing glaucoma medications

Conditions: Glaucoma; Monotherapy With Xalatan From 1 to 18 Months; Ocular Surface Disease

Summary: hypothesis: changing to travatan z therapy increases the tear film break up time of subjects on xalatan therapy presenting with ocular surface disease.

patients who have been taking xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to travatan z. test results will be recorded at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the ocular surface disease index.

Eligibility criteria:
inclusion criteria: * on xalatan monotherapy from 1 to 18 months * 18 years of age or older * has been diagnosed with ocular surface disease exclusion criteria: * special populations such as children, pregnant females, prisoners, etc.

Keywords: travatan z glaucoma tear film break up time
antitetanus vaccination for people older than 65 years.

Conditions: Tetanus

Summary: in the last ten years, more than one hundred generalized tetanus cases were declared in france. most of them were affecting people older than 70 years with an important mortality (around 28%). it is know that the only way to protect ourselves from this disease is the vaccination. in france tetanus vaccination is mandatory since 1940. nowaday none study looked specifically for the vaccination of people older than 65 years. the hypothesis is: there is a difference in the tetanus vaccination coverage for people older than 65 years depending on the demographic and medical practice of their general practitioner.


Eligibility criteria:
inclusion criteria: * patients older than 65 years consulting their attending physician in and who agreed to participate in the study. * the doctors included are general practitioners located in a liberal office in the "auvergne rhône alpes" region for which the urps ("union régional des professionnels de santé") has an email address. exclusion criteria: * none